Stockreport

Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment [Yahoo! Finance]

Taysha Gene Therapies, Inc.  (TSHA) 
PDF Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) with a $19 price target. Taysha Gene Therapies, Inc. (TSHA) Making Progress on Crucial Rett Syndrome Treatment [Read more]